| |  Dr.
Max is
Chief of the Clinical Trials Unit, Pain and
Neurosensory Mechanisms Branch, National Institute of Dental
and Craniofacial Research, NIH, in Bethesda, Maryland. After
graduating from Harvard Medical School in 1974, Dr. Max completed
residencies in internal medicine at the University of Chicago
and neurology at the New York Hospital, followed by a fellowship
in clinical pharmacology and cancer pain treatment at Memorial
Sloan-Kettering Cancer Center with Dr. Kathleen Foley, whom
he assisted in the development of the World Health Organization's
Cancer Pain Relief Program. Dr. Max has been at the NIH since
1983, where his major research interests have been
ANALGESIC
CLINICAL TRIALS AND THE CLINICAL GENETICS OF CHRONIC PAIN.
The studies of Dr.
Max and his NIDCR colleagues
have demonstrated the effectiveness of norepinephrine reuptake
blockers, adrenergic agonists, and NMDA receptor antagonists
in neuropathic pain and AMPA/kainate receptor blockade in
hyperalgesia, and have introduced methods for clinical trials
in patients with chronic pain. Dr. Max is the editor of
the standard textbook, The Design of Analgesic Clinical
Trials and the American Pain Society's Principles
of Analgesic Use and Quality Improvement Standards
for the Treatment of Acute Pain and Cancer Pain, and
is on the editorial board of Pain, Neurology,
and other journals. Dr. Max's research has been recognized
by a number of honors, including the Public Health Service
Citation and Commendation Medals and the American Pain Society's
Wilbert Fordyce Award for Clinical Investigation.
|